title: A prospective, randomized, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on lesional and nonlesional skin.
abstract: BACKGROUND
  There is a need for biomarkers to screen the effectiveness of (novel) therapeutic agents for psoriasis at an early stage.
  
  
  OBJECTIVE
  We aimed to determine which of the changes in psoriatic skin correlates best with clinical improvement 4 weeks after effective adalimumab therapy.
  
  
  METHODS
  Twenty-two psoriatic arthritis patients were randomized to receive adalimumab or placebo. T cell numbers and markers of innate immunity were estimated in lesional and nonlesional skin biopsies at baseline and after 4 weeks of treatment.
  
  
  RESULTS
  CD161+ and elastase+ dermal cells in lesional skin were significantly reduced upon 4 weeks of successful adalimumab treatment compared with placebo.
  
  
  CONCLUSIONS
  Early improvement of psoriasis lesions during adalimumab therapy is associated with a marked reduction of infiltrated dermal CD161+ T cells and elastase+ neutrophils, suggesting that these parameters could be used as biomarkers to monitor early changes after active treatment in small proof-of-concept studies of short duration.
authors.affiliation: Department of Dermatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
authors.forename: Marjan
authors.initials: M
authors.lastname: de Groot
authors.forename: Daisy I
authors.initials: DI
authors.lastname: Picavet
authors.forename: Arno W R
authors.initials: AW
authors.lastname: van Kuijk
authors.forename: Paul P
authors.initials: PP
authors.lastname: Tak
authors.forename: Jan D
authors.initials: JD
authors.lastname: Bos
authors.forename: Menno A
authors.initials: MA
authors.lastname: de Rie
authors.forename: Marcel B M
authors.initials: MB
authors.lastname: Teunissen
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy* / Q000378:metabolism; D015415:Biomarkers / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011565:Psoriasis / Q000188:drug therapy* / Q000378:metabolism; D012867:Skin / Q000187:drug effects*; D013601:T-Lymphocytes / Q000378:metabolism; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D015415:Biomarkers; D000068879:Adalimumab